US 2009/0325856 A1 · Composition Designed For The Treatment Of Multiple Sclerosis

Abstract

A composition for controlling the progression of multiple sclerosis includes at least: One conjugate between poly-lysine and at least one fatty acid, and One conjugate between poly-lysine and at least one antioxidant, and One conjugate between poly-lysine and at least one amino acid derivative.

Claims19

Dependent claims

Composition that is useful for the preparation of a medication that is designed to control the progression of multiple sclerosis, characterized in that it comprises at least:

One conjugate between poly-lysine and at least one fatty acid, and
One conjugate between poly-lysine and at least one antioxidant, and
One conjugate between poly-lysine and at least one amino acid derivative.

Dependencies are inferred from the claim text.

Facts

Application

11/915,532Filed 24 May 2006

Priority

FR 055140027 May 2005

Published

31 Dec 2009

Term ends

Not estimatedThe source records don’t support an estimate.

Classification10 codes

A61K 31/201
Having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids: having one or two double bonds,…
A61K 31/122
Ketones: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
A61K 31/198
The amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine,…:…
A61K 31/203
Having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids: retinoic acids ; Salts thereof

Abstract

Claims19

Dependent claims

Composition that is useful for the preparation of a medication that is designed to control the progression of multiple sclerosis, characterized in that it comprises at least:

One conjugate between poly-lysine and at least one fatty acid, and
One conjugate between poly-lysine and at least one antioxidant, and
One conjugate between poly-lysine and at least one amino acid derivative.

Dependencies are inferred from the claim text.

Facts

Application

11/915,532Filed 24 May 2006

Priority

FR 055140027 May 2005

Published

31 Dec 2009

Term ends

Not estimatedThe source records don’t support an estimate.

Classification10 codes

A61K 31/201
Having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids: having one or two double bonds,…
A61K 31/122
Ketones: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
A61K 31/198
The amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine,…:…
A61K 31/203
Having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids: retinoic acids ; Salts thereof

Composition Designed For The Treatment Of Multiple Sclerosis

Life of this patent

Abstract

Claims19

Composition Designed For The Treatment Of Multiple Sclerosis

Life of this patent

Abstract

Claims19